SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-178328
Filing Date
2023-06-29
Accepted
2023-06-29 12:15:30
Documents
15
Period of Report
2023-06-28
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d517782d8k.htm   iXBRL 8-K 30561
2 EX-3.1 d517782dex31.htm EX-3.1 5966
3 EX-99.1 d517782dex991.htm EX-99.1 12938
7 GRAPHIC g517782g0629201654399.jpg GRAPHIC 3147
  Complete submission text file 0001193125-23-178328.txt   191666

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ikt-20230628.xsd EX-101.SCH 2856
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20230628_lab.xml EX-101.LAB 19482
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20230628_pre.xml EX-101.PRE 12158
9 EXTRACTED XBRL INSTANCE DOCUMENT d517782d8k_htm.xml XML 3676
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 231055882
SIC: 2836 Biological Products, (No Diagnostic Substances)